Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

20 trials with published results (35%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

3.5%

2 terminated out of 57 trials

Success Rate

93.1%

+6.6% vs benchmark

Late-Stage Pipeline

46%

26 trials in Phase 3/4

Results Transparency

74%

20 of 27 completed with results

Key Signals

20 with results93% success

Data Visualizations

Phase Distribution

44Total

Not Applicable (14)

P 2 (4)

P 3 (20)

P 4 (6)

Trial Status

Completed27

Recruiting18

Unknown7

Terminated2

Active Not Recruiting2

Withdrawn1

Trial Success Rate

93.1%

Benchmark: 86.5%

Based on 27 completed trials

Clinical Trials (57)

Showing 20 of 20 trials

NCT07018700Phase 3RecruitingPrimary

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07496034Phase 3RecruitingPrimary

Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine: A Double-Blind Randomized Controlled Trial

NCT05711394Phase 3RecruitingPrimary

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05897320Phase 3RecruitingPrimary

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

NCT05734625Phase 2RecruitingPrimary

Efficacy of Nerve Blocks for Episodic Migraine

NCT06047457Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06625060Phase 2RecruitingPrimary

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

NCT06248671Phase 2RecruitingPrimary

Prophylactic Treatment With Atorvastatin for Episodic Migraine.

NCT03432286Phase 3Active Not RecruitingPrimary

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

NCT06603558Recruiting

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

NCT04686136Phase 3CompletedPrimary

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

NCT05028569Phase 3TerminatedPrimary

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

NCT07159750Recruiting

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

NCT05207865Phase 4Completed

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

NCT07103694RecruitingPrimary

i-NEED: NEw migrainE Drugs Database

NCT04437433Phase 3Completed

A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine